Form 4: Adaptive Biotechnologies CFO Kyle Piskel Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Chief Financial Officer of Adaptive Biotechnologies, Kyle Piskel, reports acquisition and disposal of common stock.
Summary
- On May 15, 2024, Kyle Piskel, the Chief Financial Officer of Adaptive Biotechnologies, reported changes in beneficial ownership of the company's common stock.
- Piskel acquired 31,260 shares of common stock.
- Piskel disposed of an unspecified amount of shares.
- Following the reported transactions, Piskel beneficially owns 154,578 shares of Adaptive Biotechnologies common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting changes in beneficial ownership, which doesn't inherently convey positive or negative sentiment. It's a factual disclosure.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. These filings are monitored by investors to gauge management's sentiment and confidence in the company's prospects.
Stakeholder Impact
- Shareholders may be interested in the trading activity of company insiders as an indicator of management's view of the company's value and prospects.
Key Dates
| Date | Description |
|---|---|
| 05/15/2024 | Date of transaction: acquisition and disposal of common stock |
| 05/17/2024 | Date of signature for the report |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.